BUZZ-MAIA Biotechnology rises on lung cancer drug trial data

Shares of cancer drug developer MAIA Biotechnology MAIA.A rise 16.4% to $2.20

Co says its experimental drug, THIO, helped patients with a type of lung cancer live for a median of 16.9 months, in mid-stage trial

THIO was generally well-tolerated in patients who had received multiple previous treatments, co says

Co says it is considering the possibility of accelerated FDA approval of THIO

THIO gained 66.4% in 2024